GBA1 and Parkinson disease: Although several studies agree on differences in GBA1 activity in PD and DLB patients’ brain lysates [9–11], there are contradictory observations from human CSF [21,24–26], raising the possibility that assay conditions (such as sodium taurocholate) may explain these differences.